An interventional study of Neurotomy of the medial sensory articular branches in Osteoarthritis (OA) of the Knee, Knee Pain Arthritis and Chronic Knee Pain, sponsored by FUSMobile Inc.. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by FUSMobile Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 205 studies in Osteoarthritis with a site in Canada — 25 open to participants now, 46 under way, 4 of them phase 3. Osteoarthritis · Canada.
Among the 205 studies in Osteoarthritis with a site in Canada, this one is the 165th largest by planned enrollment of the 176 interventional ones that give a count, is one of 7 that started in 2026, is one of 101 with no phase, reaches primary completion later than 13 of the 45 other live ones, and was the 197th registered.
2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.
Browse Osteoarthritis studies →25 of the 205 studies in Osteoarthritis with a site in Canada are open now. Recruiting first, the newest first:
Pfizer · Sites in Canada, United States
Ages 18+
University of British Columbia · Sites in Canada
Ages 50+
St. Joseph's Healthcare Hamilton · Sites in Canada
Ages 18+
Eli Lilly and Company · Sites in Canada, United States, Argentina and 10 more countries
Ages 18+
Université du Québec à Trois-Rivières · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
205 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 32 · Phase 3 31 · Phase 4 13
First in 1996; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 80 across 2,242 interventional studies indexed under Osteoarthritis.
Median enrollment 98 across the 176 interventional studies, 132 across the 29 observational. Of the 130 that completed or were terminated, 37 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 205 have an industry lead sponsor. The 10 most frequent:
FUSMobile Inc. is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
FUSMobile Inc. has 1 study filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
15 of the studies in Osteoarthritis with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06966206Phase 3St. Joseph's Healthcare HamiltonMultiprofen-CC to Reduce Pain in Hand Arthritis | 2026-12-31 |
| NCT03626038Zimmer BiometPost Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System | 2026-12 |
| NCT04634773Ottawa Hospital Research InstituteUnravelling the Etiology of Shoulder Osteoarthritis | 2026-12 |
| NCT06681142University of AlbertaPharmacist-physiotherapist Collaborative Management for Early Knee Osteoarthritis | 2026-12-01 |
| NCT07178951FUSMobile Inc.Neurolysis for the Treatment of Medial Chronic Knee Pain Due to Osteoarthritis | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 205 studies in Osteoarthritis with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study involves the use of sound waves to block pain signals caused by osteoarthritis of the knee. The sound waves are tightly focused on a specific area of the nerve. The sound waves cause a break in the nerve which carries pain signals. Sound waves transmit through the skin so there is no need for needles. The procedure takes approximately one hour. The device has been approved in Health Canada and Europe for the treatment of lower back pain. This study is to evaluate the use of the same device for people in Canada who have knee pain related to osteoarthritis.
The research staff will provide a detailed description of the procedure to the study participant live, allowing time for the participant to ask questions. Once the participant agrees to be in the study, an informed consent form will be signed.
Throughout the study, the research team will closely follow the participants health as it is related to their knee. The participant will have a physical exam of their knee and a pressure algometry test at each onsite visit. They will also rate their pain level on a numerical scale, provide a history of medications taken, and complete several quality of life questionnaires.
The participant will be asked to take their usual pain medication prior to the procedure. The study doctor may also provide additional medication depending on the study participants situation.
The study procedure will last approximately 1 hour. The procedure will take place using a standard X-ray device which allows the study doctor to see the structure of the knee and allow for location of the nerve causing knee pain.
The study device will use ultrasound waves to cause damage to the nerve of the knee where the pain is generated. The goal is to interrupt the pain signal pathway. The ultrasound waves go through the skin so no needles or incisions are needed.
It is unknown how much pain relief the participant will feel or how long it will last. The purpose of the study is to evaluate ten people who have the study procedure. If the study results are good, the manufacturer of the device plans to open up a larger study to involve more study participants.
For participants who have access and a MRI is not contraindicated, a follow-up MRI exam will be performed from day 5 to 7 of the participant's knee.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Ablation of sensory nerves in the knee joint
Device: Neurotomy of the medial sensory articular branches
Non-invasive thermal ablation of the medial sensory articular branches of the knee joint
Also known as: Nerve ablation, genicular nerve ablation
A positive clinical outcome will be measured by a 2-point reduction in the Numerical Rating Score (NRS)
The NRS score is a 10 point scale, 0 to 10, with 0 meaning "no pain" and 10 meaning "worst possible pain"; the NRS score will be measured at baseline and all follow-up intervals - 2 days, 7 days, 1 month, 3 months, and 6 months..
Time frame: Baseline score will be compared to post procedure intervals at 2 days, 7 days, 1 month, 3 months, and 6 months.
Safety will be measured by the incidence and severity of treatment-related adverse events.
Adverse events will be evaluated throughout the study.
Time frame: Adverse events will be evaluated at baseline and post procedure - 2 days, 7 days, 1 month, 3 months, and 6 months.
Lesion size and location
Lesion size and location as shown in MRI images post treatment as available
Time frame: Participants will have an MRI 5-7 days post treatment when feasible and not contraindicated
Procedure time (in minutes)
Procedure time will be documented from start to finish
Time frame: The time of the procedure will be documented in minutes.
Radiation exposure (in seconds)
The procedure is completed using fluroscopy. The fluroscopy time is calculated by the C-Arm. This number will be documented.
Time frame: The fluoroscopy time will be calculated and documented during the procedure.
Periprocedural analgesic/sedative requirement
Analgesic/sedatives used during the procedure will be documented.
Time frame: During the procedure, analgesic/sedative use will be documented.
Change in Pain Pressure Threshold (PPT) as measured on the tibial plateau.
A pressure algometry device will be used to measure the pain pressure threshold throughout the study.
Time frame: The PPT will be evaluated and documented at baseline and at follow-up intervals - 2 days, 7 days, 1 month, 3 months, and 6 months
Change in score Patient Global Impression of Change (PGIC)
The PGIC questionnaire will be given to participants during their onsite follow up visits.
Time frame: PGIC questionnaires will be provided to participants 1 month, 3 months, and 6 months post procedure.
Plan to share: No — This is a pilot study. If results are positive, we plan to organize a larger pivotal study.
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Dec 2026, 3 months after the start.
Of 135 industry-sponsored interventional studies with no phase under Osteoarthritis, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 81. This study's planned 3 months is below that.
Counting every sponsor, half of 713 studies reached it within 28 months; a quarter within 11 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
FUSMobile Inc.